Venous thromboembolism prophylaxis with anticoagulation in septic patients: A prospective cohort study

QJM: An International Journal of Medicine

Volumn 108, Issue 3, 2015, Pages 197-204

  Zusman, O ^a   Paul, M ^b,c   Farbman, L ^a   Daitch, V ^a   Akayzen, Y ^a   Witberg, G ^a   Avni, T ^a,c   Gafter Gvili, A ^a,c   Leibovici, L ^a,c  

^a RABIN MEDICAL CENTER   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; HEPARIN; HYPERTENSIVE FACTOR; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; THROMBOCYTE COUNT; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; ACUTE DISEASE; CASE CONTROL STUDY; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; HOSPITALIZATION; MULTICENTER STUDY; RISK FACTOR; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; ANTICOAGULANTS; CASE-CONTROL STUDIES; FEMALE; HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SEPSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84924431141     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcu183     Document Type: Article

References (29)

1. Anderson FA, Zayaruzny M, Heit JA, Fidan D, Cohen AT. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007; 82: 777-82.
2. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371:387-94.
3. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based casecontrol study. Archives of internal medicine. 2000; 160:809-15.
4. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-800.
5. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110:874-9.
6. Robinson KS, Anderson DR, Gross M, Petrie D, Leighton R, Stanish W, et al. Accuracy of screening compression ultrasonography and clinical examination for the diagnosis of deep vein thrombosis after total hip or knee arthroplasty. Can J Surg J canadien de chirurgie. 1998; 41:368-73.
7. Lederle FA, Zylla D, MacDonald R, Wilt TJ. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2011; 155:602.
8. Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 2011; 365:2463-72.
9. Maynard G, Stein J. Preventing Hospital-Acquired Venous Thromboembolism: A Guide for Effective Quality Improvement. Rockville, MD: Agency for Healthcare Research and Quality, 2008.
10. Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P. Venous thromboembolism prophylaxis in hospitalized patients:a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011; 155:625-32.
11. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in nonsurgical patients:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl.):e195S-226S.
12. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism:the Padua Prediction Score. J Thromb Haemost 2010; 8:2450-7.
13. Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet 1996; 347:1357-61.
14. Vardi M, Ghanem-Zoubi NO, Zidan R, Yurin V, Bitterman H. Venous thromboembolism and the utility of the Padua Prediction Score in patients with sepsis admitted to internal medicine departments. J Thromb Haemost 2013; 11:467-73.
15. Rothwell PM. External validity of randomised controlled trials: ''to whom do the results of this trial apply?'' Lancet 2005; 365: 82-93.
16. Dans AL, Dans LF, Guyatt GH, Richardson S. Users' guides to the medical literature: XIV. How to decide on the applicability of clinical trial results to your patient. Evidence-Based Medicine Working Group. JAMA 1998; 279:545-9.
17. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36:309-32.
18. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-10.
19. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Statistical methods in medical research 2007; 16:219-42.
20. Sekhon JS. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw 2011; 42:1-52.
21. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/ (11 September 2014, date last accessed).
22. Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 2011; 42:1-28.
23. Vardi M, Steinberg M, Haran M, Cohen S. Benefits versus risks of pharmacological prophylaxis to prevent symptomatic venous thromboembolism in unselected medical patients revisited. Meta-analysis of the medical literature. J Thromb Thrombolysis 2012; 34:11-9.
24. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146:278-88.
25. Prasad V, Rho J, Cifu A. The diagnosis and treatment of pulmonary embolism: a metaphor for medicine in the evidence-based medicine era. Arch Intern Med 2012; 172:955-8.
26. Mahe I, Bergmann JF, d'Azemar P, Vaissie JJ, Caulin C. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study. Eur J Clin Pharmacol 2005; 61:347-51.
27. Greig MF, Rochow SB, Crilly MA, Mangoni AA. Routine pharmacological venous thromboembolism prophylaxis in frail older hospitalised patients: where is the evidence? Age and ageing 2013; 42: 428-34.
28. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012; 12:MR000033.
29. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations:2000-2005. JAMA 2006; 295:2270-4.